Published in Medical Letter on the CDC and FDA, February 25th, 2007
"The completion of patient enrollment into the CLARITY pivotal trial is a major milestone in the development program of oral cladribine," said Franck Latrille, Merck Serono's head of product development. "It brings us one step closer to our objective of offering patients the first oral therapy for first line treatment of multiple sclerosis, with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.